A prospective protocol for nasopharyngeal carcinoma in children and adolescents: The Italian Rare Tumors in Pediatric Age (TREP) project

Cancer

Volumn 118, Issue 10, 2012, Pages 2718-2725

  Casanova, Michela ^a   Bisogno, Gianni ^b   Gandola, Lorenza ^a   Cecchetto, Giovanni ^b   Di Cataldo, Andrea ^c   Basso, Eleonora ^d   Indolfi, Paolo ^e   D'Angelo, Paolo ^f   Favini, Francesca ^a   Collini, Paola ^a   Potepan, Paolo ^a   Ferrari, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f G Di Cristina Children's Hospital   (Italy)

Author keywords

chemotherapy; children and adolescents; nasopharyngeal carcinoma; radiotherapy; rare pediatric tumors; Rare Tumors in Pediatric Age (TREP) project; sequelae

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADOLESCENT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHILD; CHILD HEALTH CARE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INFANT; LIVER TOXICITY; LONG TERM CARE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION INJURY; SCHOOL CHILD; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

ADOLESCENT; CHEMORADIOTHERAPY; CHILD; DISEASE-FREE SURVIVAL; DNA, VIRAL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84860691781     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26528     Document Type: Article

References (39)

1. Bray F, Haugen M, Moger TA, et al. Age-incidence curves of nasopharyngeal carcinoma worldwide: bimodality in low-risk populations and aetiologic implications. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2356-2365.
2. Pastore G, De Salvo GL, Bisogno G, et al. Evaluating the access to pediatric cancer care centers of children and adolescents with rare tumors in Italy: the TREP project. Pediatr Blood Cancer. 2009; 53: 152-155.
3. Sultan I, Casanova M, Ferrari A, et al. Differential features of nasopharyngeal carcinoma in children and adults: a SEER study. Pediatr Blood Cancer. 2010; 55: 279-284.
4. Ferrari A, Casanova M, Massimino M, Sultan I,. Peculiar features and tailored management of adult cancers occurring in pediatric age. Expert Rev Anticancer Ther. 2010; 10: 1837-1851.
5. Rodriguez-Galindo C, Wofford M, Castleberry RP, et al. Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. Cancer. 2005; 103: 850-857.
6. Mertens R, Granzen B, Lassay L, et al. Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC-91-GPOH). Cancer. 2005; 104: 1083-1089.
7. Ozyar E, Selek U, Laskar S, et al. Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network study. Radiother Oncol. 2006; 81: 39-46.
8. Pao WJ, Hustu HO, Douglass EC, et al. Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients. Int J Radiat Oncol Biol Phys. 1989; 17: 299-305.
9. Wei WI, Sham JS,. Nasopharyngeal carcinoma. Lancet. 2005; 365: 2041-2054.
10. Chan SH, Ng WT, Kam KL, et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys. 2009; 73: 1335-1342.
11. Chen MC, Feng IJ, Lu CH, et al. The incidence and risk of second primary cancers in patients with nasopharyngeal carcinoma: a population-based study in Taiwan over a 25-year period (1979-2003). Ann Oncol. 2008; 19: 1180-1186.
12. Ulger S, Ulger Z, Yildiz F, Ozyar E,. Incidence of hypothyroidism after radiotherapy for nasopharyngeal carcinoma. Med Oncol. 2007; 24: 91-94.
13. Ka Leung Cheuk D, Billups CA, Martin MG, et al. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer. 2011; 117: 197-206.
14. Ferrari A, Bisogno G, De Salvo GL, et al. The challenge of very rare tumours in childhood: the Italian TREP project. Eur J Cancer. 2007; 43: 654-659.
15. Casanova M, Ferrari A, Gandola G, et al. Undifferentiated nasopharyngeal carcinoma in children and adolescents: comparison between staging systems. Ann Oncol. 2001; 12: 1157-1162.
16. Al-Sarraf M, Leblanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998; 16: 1310-1317.
17. Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004; 22: 4604-4612.
18. Ng SH, Chan SC, Yen TC, et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging. 2009; 36: 12-22.
19. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350: 2461-2470.
20. Fleming ID, Cooper JS, Henson DE, et al, eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
22. Kaplan EL, Meier P,. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457-481.
23. Frikha M, Toumi N, Ghorbel L, et al. Pediatric nasopharyngeal carcinoma: anatomoclinic aspects, therapeutic results and evolutive particularities. Cancer Radiother. 2010; 14: 169-175.
24. Kupeli S, Varan A, Ozyar E, et al. Treatment results of 84 patients with nasopharyngeal carcinoma in childhood. Pediatr Blood Cancer. 2006; 46: 454-458.
25. Afqir S, Ismaili N, Alaoui K, et al. Nasopharyngeal carcinoma in adolescents: a retrospective review of 42 patients. Eur Arch Otorhinolaryngol. 2009; 266: 1767-1773.
26. Saeed H, Zaidi A, Adhi M, et al. Pediatric nasopharyngeal carcinoma: a review of 27 cases over 10 years at Shaukat Khanum Memorial Cancer Hospital and Research Center, Pakistan Asian Pac J Cancer Prev. 2009; 10: 917-920.
27. Orbach D, Brisse H, Helfre S, et al. Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: radiotherapy dose adaptation after chemotherapy response to minimize late effects. Pediatr Blood Cancer. 2008; 50: 849-853.
28. Laskar S, Bahl G, Muckaden M, et al. Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 72: 728-736.
29. Sterzing F, Stoiber EM, Nill S, et al. Intensity-modulated radiotherapy (IMRT) in the treatment of children and adolescents-a single institution's experience and a review of the literature [serial online]. Radiat Oncol. 2009; 4: 37.
30. Chen YY, Zhao C, Wang J, et al. Intensity-modulated radiation therapy reduces radiation-induced trismus in patients with nasopharyngeal carcinoma: a prospective study with >5 years of follow-up. Cancer. 2011; 117: 2910-2916.
31. Xiao WW, Huang SM, Han F, et al. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer. 2011; 117: 1874-1883.
32. Hsin CH, Chen TH, Young YH, et al. Comparison of otologic complications between intensity-modulated and 2-dimensional radiotherapies in nasopharyngeal carcinoma patients. Otolaryngol Head Neck Surg. 2010; 143: 662-668.
33. Louis CU, Paulino AC, Gottschalk S, et al. A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT. J Pediatr Hematol Oncol. 2007; 29: 500-505.
34. Varan A, Ozyar E, Corapcioglu F, et al. Pediatric and young adult nasopharyngeal carcinoma patients treated with preradiation cisplatin and docetaxel chemotherapy. Int J Radiat Oncol Biol Phys. 2009; 73: 1116-1120.
35. Ayan I, Kaytan E, Ayan N,. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003; 4: 13-21.
36. Pathmanathan R, Prasad U, Sadler R, et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med. 1995; 333: 693-698.
37. Comoli P, De Palma R, Siena S, et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol. 2004; 15: 113-117.
38. Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005; 105: 1898-1904.
39. Ji MF, Wang DK, Yu YL, et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer. 2007; 96: 623-630.